{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:27:02Z","timestamp":1793957222563,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107911","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:44:12Z","timestamp":1788677052000},"page":"107911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of potential serum biomarkers for individuals at risk of multiple sclerosis highlights SPP1"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2775-5932","authenticated-orcid":false,"given":"Kristin","family":"Mounts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunDuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Oyegunle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tradite","family":"Neziraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan V.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyater","family":"Ngouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya U.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2505","authenticated-orcid":false,"given":"Philip L.","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107911_bib0014","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.410280514","article-title":"Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis","volume":"28","author":"Adachi","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190252","article-title":"Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis","volume":"13","author":"Agah","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2026.107911_bib0039","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"\u00c5kesson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2026.107911_bib0024","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fnins.2019.01026","article-title":"Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients","volume":"13","author":"Bai","year":"2019","journal-title":"Front. Neurosci"},{"key":"10.1016\/j.msard.2026.107911_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0404.1991.tb04955.x","article-title":"Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis","volume":"84","author":"Bansil","year":"1991","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2026.107911_bib0005","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/jpm12091430","article-title":"A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis","volume":"12","author":"Barizzone","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2026.107911_bib0015","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/cen3.12253","article-title":"Elevated levels of soluble CD26 and CD30 in multiple sclerosis","volume":"6","author":"Basnyat","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107911_bib0002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0028","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1352458510382247","article-title":"Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis","volume":"17","author":"B\u00f6rnsen","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107911_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200335","article-title":"Temporal Dynamics of Plasma Neurofilament Light in Blood Donors With Preclinical Multiple Sclerosis","volume":"12","author":"Britze","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2026.107911_bib0033","first-page":"339","article-title":"Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity","volume":"13","author":"Caligaris-Cappio","year":"1995","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.msard.2026.107911_bib0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/1352458511433063","article-title":"Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis","volume":"18","author":"Cant\u00f3","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107911_bib0048","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1126\/science.1062960","article-title":"The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease","volume":"294","author":"Chabas","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.msard.2026.107911_bib0046","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.02.020","article-title":"Osteopontin gene haplotypes correlate with multiple sclerosis development and progression","volume":"163","author":"Chiocchetti","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107911_bib0026","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jneuroim.2004.09.004","article-title":"Plasma osteopontin levels in multiple sclerosis","volume":"158","author":"Comabella","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107911_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1729989","article-title":"Serum CHI3L1 levels correlate with disease activity in rheumatoid arthritis and reveal potential molecular mechanisms","volume":"16","author":"Deng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41582-025-01164-w","article-title":"Towards primary prevention of multiple sclerosis","volume":"22","author":"Dobson","year":"2026","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0038","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2249.1997.d01-991.x","article-title":"Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease","volume":"108","author":"Giacomelli","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0025","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s11695-009-9917-4","article-title":"YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss","volume":"19","author":"Hempen","year":"2009","journal-title":"Obes. Surg."},{"key":"10.1016\/j.msard.2026.107911_bib0013","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107911_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2015.06.015","article-title":"Biomarkers in multiple sclerosis","volume":"161","author":"Housley","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni1415","article-title":"Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells","volume":"8","author":"Hur","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0012","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/acn3.51990","article-title":"Plasma proteomic profiles of UK Biobank participants with multiple sclerosis","volume":"11","author":"Jacobs","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/1352458513503052","article-title":"Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development","volume":"20","author":"Kivis\u00e4kk","year":"2014","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107911_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12974-024-03036-4","article-title":"Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes","volume":"21","author":"Kodosaki","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2026.107911_bib0020","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.rmed.2006.12.006","article-title":"A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker","volume":"101","author":"Kruit","year":"2007","journal-title":"Respir. Med."},{"key":"10.1016\/j.msard.2026.107911_bib0042","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1515\/cclm-2012-0177","article-title":"Stability of osteopontin in plasma and serum","volume":"50","author":"Lanteri","year":"2012","journal-title":"Clin. Chem. Lab. Med. CCLM"},{"key":"10.1016\/j.msard.2026.107911_bib0022","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.182.3.1541","article-title":"Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses","volume":"182","author":"Maier","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0032","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0090-1229(89)90140-2","article-title":"Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases","volume":"50","author":"Manoussakis","year":"1989","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.msard.2026.107911_bib0016","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.51.4.1156","article-title":"Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis","volume":"51","author":"McMillan","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107911_bib0044","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.4049\/jimmunol.181.11.7480","article-title":"Increased Osteopontin Expression in Dendritic Cells Amplifies IL-17 Production by CD4+ T Cells in Experimental Autoimmune Encephalomyelitis and in Multiple Sclerosis","volume":"181","author":"Murugaiyan","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105004","article-title":"A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis","volume":"79","author":"Nowak-Kiczmer","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107911_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03173-3","article-title":"Osteopontin levels are associated with late-time lower regional brain volumes in multiple sclerosis","volume":"11","author":"Orsi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107911_bib0047","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000085654","volume":"12","author":"Pellegrini","year":"2005","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.msard.2026.107911_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000897","article-title":"Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events","volume":"3","author":"Ridker","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.msard.2026.107911_bib0043","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-014-8491-6","article-title":"Effects of serum and plasma matrices on multiplex immunoassays","volume":"58","author":"Rosenberg-Hasson","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.msard.2026.107911_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2024.113699","article-title":"Sources of variability in Luminex bead-based cytokine assays: Evidence from twelve years of multi-site proficiency testing","volume":"531","author":"Rountree","year":"2024","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.msard.2026.107911_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119681","article-title":"Biomarkers of Inflammation and Axonal Degeneration\/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF\/Serum Ratio to a Biomarker Panel","volume":"10","author":"Stilund","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2026.107911_bib0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.msard.2026.107911_bib0037","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2249.1999.00881.x","article-title":"The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA)","volume":"116","author":"Tak","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.1990.tb05398.x","article-title":"Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus","volume":"82","author":"ter Borg","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107911_bib0027","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ana.10606","article-title":"Elevated osteopontin levels in active relapsing-remitting multiple sclerosis","volume":"53","author":"Vogt","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0034","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar3316","article-title":"Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.msard.2026.107911_bib0009","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ana.24560","article-title":"Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk","volume":"79","author":"Xia","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107911_bib0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2016.5056","article-title":"Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members","volume":"74","author":"Xia","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107911_bib0003","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms23115877","article-title":"Current and Future Biomarkers in Multiple Sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107911_bib0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3892\/mmr.2013.1522","article-title":"Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans","volume":"8","author":"You","year":"2013","journal-title":"Mol. Med. Rep."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:41:49Z","timestamp":1793954509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"alternative-id":["S2211034826009466"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107911","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of potential serum biomarkers for individuals at risk of multiple sclerosis highlights SPP1","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107911"}}